AstraZeneca loses appeal on lung cancer drug rights in India
The Intellectual Property Appellate Board (I PAB) has dismissed multinational drug major AstraZeneca's appeal against refusal of patent to its lung cancer drug, Gefitinib, on grounds of known prior use. in 2007, the Indian Patent Office had rejected ...
India rejects AstraZeneca patent appealTimes of India
Patents appeal board rejects AstraZeneca's patent plea on cancer drugEconomic Times

all 28 news articles »